Physician profile
Jay E Fisher
NPI 1811970171
$135,564.75
in general payments reported to CMS, 2019-2025
36 companies · $3,465 in 2025
The $3,465 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $17K · 2021: $37K · 2022: $18K · 2023: $16K · 2024: $5,960 · 2025: $3,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $2,793 · Travel and Lodging: $28.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,662.50 |
| Food and Beverage | $2,792.80 |
| Travel and Lodging | $28.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,677.07 | 2019-2025 | |
| Acessa Health INC. | $53,209.67 | 2019-2024 | Acessa Provu System |
| Bayer Healthcare Pharmaceuticals INC. | $8,422.23 | 2021-2025 | |
| Meditrina | $6,761.78 | 2022-2024 | |
| Hologic Sales and Service, LLC | $4,338.94 | 2019-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Acessa Provu System, Myosure Tissue Removal Device |
| Sumitomo Pharma America, INC. | $511.40 | 2023-2025 | Myfembree, Gemtesa |
| Gynesonics, INC. | $337.91 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Myovant Sciences INC. | $140.74 | 2021-2022 | |
| Pfizer INC. | $125.22 | 2022-2024 | |
| Astellas Pharma US INC | $106.10 | 2024-2025 | Veozah |
| Daiichi Sankyo INC. | $99.03 | 2019-2023 | Injectafer |
| Ethicon US, LLC | $80.31 | 2023 | Surgicel Nu-Knit, Harmonic, Enseal |
| Therapeuticsmd, INC. | $67.00 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $66.27 | 2022-2023 | |
| Intuitive Surgical, INC. | $57.66 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $52.95 | 2022-2023 | Accrufer |
| Avion Pharmaceuticals | $52.03 | 2020-2023 | Balcoltra |
| Coopersurgical, INC. | $46.86 | 2022-2025 | Paragard T 380a |
| Aspira Women'S Health INC | $43.27 | 2022 | |
| Millicent US INC | $39.07 | 2024-2025 | Femring, Intrarosa |
| Axonics, INC. | $38.31 | 2024 | Axonics, Bulkamid |
| Organon LLC | $33.45 | 2022-2023 | Nexplanon |
| Hologic INC | $30.00 | 2021 | |
| Allergan, INC. | $29.54 | 2019 | |
| Smith+Nephew, INC. | $22.85 | 2020 | |
| Merck Sharp & Dohme LLC | $21.03 | 2020 | |
| Sage Therapeutics, LLC | $20.63 | 2025 | Zurzuvae |
| Olympus America INC. | $20.30 | 2024 | Olympus, Olympus |
| Becton, Dickinson and Company | $18.79 | 2019 | |
| Boston Scientific Corporation | $18.23 | 2025 | Axonics |
| Exact Sciences Corporation | $17.51 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Pharmaceuticals INC. | $16.50 | 2022 | |
| Mimedx Group, INC. | $14.49 | 2025 | |
| Channel Medsystems, INC. | $13.99 | 2025 | |
| Duchesnay USA Incorporated | $13.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.